Search

Your search keyword '"Debruyne, Frans"' showing total 782 results
Start Over Author "Debruyne, Frans"
782 results on '"Debruyne, Frans"'

5. A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging–directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men

Author

Wagensveld, Ivo M., Osses, Daniel F., Groenendijk, Pieter M., Zijta, Frank M., Busstra, Martijn B., Rociu, Elena, Barentsz, Jelle O., Michiel Sedelaar, J.P., Arbeel, Berber, Roeleveld, Ton, Geenen, Remy, Koeter, Ingrid, van der Meer, Saskia A., Cappendijk, Vincent, Somford, Rik, Klaver, Sjoerd, Van der Lely, Hans, Wolters, Tineke, Hellings, Willem, Leter, Maicle R., Van der Poel, Henk G., Heijmink, Stijn W.T.P.J., Debruyne, Frans, Immerzeel, Jos, Leijte, Joost, van Roermund, Joep, Miclea, Razvan, Planken, Erik, Vis, André N., Jan de Jong, Igle, Tijsterman, Jasper, Wolterbeek, Derk, Claessen, Anoesjka, Vrijhof, Eric, Nederend, Joost, Van Leenders, Geert J.L.H., Bangma, Chris H., Krestin, Gabriel P., Remmers, Sebastiaan, and Schoots, Ivo G.

Published
2022
Full Text
View/download PDF

6. The Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients Shows the Importance of Estrogens in Males.

Author

Bennink, Herjan J T Coelingh, Prowse, Amanda, Egberts, Jan F M, Debruyne, Frans M J, Huhtaniemi, Ilpo T, and Tombal, Bertrand

Subjects
PROSTATE cancer patients, ESTRADIOL, ESTROGEN, ANDROGENS, ANDROGEN deprivation therapy
Abstract

The role of estradiol (E2; an estrogen) in men needs to be more appreciated. In this review, we address the clinical situations that allow the study of the clinical consequences of E2 deficiency in men and discuss the effects of restoration of levels of this reproductive steroid hormone. In men with advanced prostate cancer (PCa) undergoing androgen deprivation therapy (ADT), E2 is suppressed along with testosterone, leading to side effects affecting the quality of life. These include hot flashes, arthralgia, fatigue, mood changes, cognition problems, weight gain, bone loss, and increased risk of cardiovascular disease. Transdermal E2 alone for ADT has shown equivalent testosterone suppression compared to gonadotropin-releasing hormone (GnRH) agonists while also preventing estrogen-deficiency side effects, including hot flashes and bone loss. Co-treatment of ADT with fetal estrogen estetrol (E4) has shown significant improvements of estrogen-deficiency symptoms. These observations emphasize the need to raise awareness of the importance of estrogens in men among clinicians and the lay public. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

Author

Coelingh Bennink, Herjan J.T., van Moorselaar, Jeroen A., Crawford, E. David, Roos, Erik P.M., Somford, Diederik M., Roeleveld, Ton A., de Haan, Tjard D., van Melick, Harm H.E., Reisman, Yacov, Zimmerman, Yvette, van Osta, Gonnie, Krijgh, Jan, Shore, Neal D., Saad, Fred, Schally, Andrew V., and Debruyne, Frans M.J.

Published
2021
Full Text
View/download PDF

10. Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormonee-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

Author

Crawford, E. David, Hafron, Jason M., Debruyne, Frans, Wallis, Christopher, Chang, Steven, and Garnick, Marc B.

Abstract

Purpose: Luteinizing hormoneereleasing hormone (LHRH) agonists are believed to have higher cardiovascular risk relative to gonadotropin-releasing hormone (GnRH) antagonists. However, previous studies have not consistently demonstrated this. We used real-world clinical practice data to evaluate differences in major adverse cardiovascular events (MACE) risk between LHRH agonists compared to a GnRH antagonist following androgen deprivation therapy (ADT) initiation. Materials and Methods: We performed a retrospective analysis of data in the Decision Resources Group (now Clarivate) Real World Evidence repository, which represents >300 million US patients from 1991 to 2020 across all US regions. Patients with prostate cancer who received at least 1 injection of ADT were included. The risks of MACE and all-cause mortality as independent endpoints were evaluated, Kaplan-Meier curves were constructed, and associations between MACE and all available confounding risk factors were evaluated by Cox regression analysis using Statistical Package for the Social Sciences. Results: A total of 45,059 men with prostate cancer treated with ADT were analyzed. Overall, the risks of MACE and all-cause mortality were slightly lower in the first year after ADT initiation compared to subsequent years. MACE risk was higher for the GnRH antagonist compared to LHRH agonists (HR[1.62; 95% CI 1.21-2.18, P = .001). The risk of all-cause mortality was also higher for the GnRH antagonist vs LHRH agonists (HR[1.87; 95% CI 1.39-2.51, P < .001). Conclusions: The adjusted incidence of MACE was higher for men treated with the GnRH antagonist compared to the LHRH agonists. The demographic and risk factors with the greatest impact on MACE risk were higher age, baseline metastasis, oncology (vs urology) setting, personal MACE history, antagonist (vs agonist), tobacco history, White (vs Black) race, and lower BMI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME)

Author

Maggi, M., Behre, H.M., Meuleman, E., Dohle, G., Arver, S., Wu, F., Porst, H., Jones, T.H., Quinton, R., Lenzi, A., Bouloux, P.-M., Morales, A.M., Hackett, G., Stroberg, P., Maggio, M., Cruz, N., Balercia, G., Yassin, A., Reisman, C., Bassas, L., Pescatori, E., Salamanca, J.I. Martinez, Otero, J. Romero, Jockenhoevel, F., Debruyne, F., Rosen, Raymond C., Wu, Frederick, Behre, Hermann M., Porst, Hartmut, Meuleman, Eric J.H., Maggi, Mario, Romero-Otero, Javier, Martinez-Salamanca, Juan I., Jones, Thomas Hugh, Debruyne, Frans M.J., Kurth, Karl-Heinz, Hackett, Geoff I., Quinton, Richard, Stroberg, Peter, Reisman, Yacov, Pescatori, Edoardo S., Morales, Antonio, Bassas, Lluis, Cruz, Natalio, Cunningham, Glenn R., and Wheaton, Olivia A.

Published
2017
Full Text
View/download PDF

14. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

Author

Azzouzi, Abdel-Rahmène, Vincendeau, Sébastien, Barret, Eric, Cicco, Antony, Kleinclauss, François, van der Poel, Henk G, Stief, Christian G, Rassweiler, Jens, Salomon, Georg, Solsona, Eduardo, Alcaraz, Antonio, Tammela, Teuvo T, Rosario, Derek J, Gomez-Veiga, Francisco, Ahlgren, Göran, Benzaghou, Fawzi, Gaillac, Bertrand, Amzal, Billy, Debruyne, Frans M J, Fromont, Gaëlle, Gratzke, Christian, and Emberton, Mark

Published
2017
Full Text
View/download PDF

15. Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

Author

Coelingh Bennink, Herjan J T, primary, Krijgh, Jan, additional, Egberts, Jan F M, additional, Slootweg, Maria, additional, van Melick, Harm H E, additional, Roos, Erik P M, additional, Somford, Diederik M, additional, Zimmerman, Yvette, additional, Schultz, Iman J, additional, Clarke, Noel W, additional, van Moorselaar, R Jeroen A, additional, and Debruyne, Frans M J, additional

Published
2022
Full Text
View/download PDF

23. Introduction

Author

Barentsz, Jelle O., Debruyne, Frans M. J., Ruijs, Sjef H. J., Barentsz, Jelle O., Debruyne, Frans M. J., and Ruijs, Sjef H. J.

Published
1990
Full Text
View/download PDF

24. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men

Author

Debruyne, Frans M.J., Behre, Hermann M., Roehrborn, Claus G., Maggi, Mario, Wu, Frederick C.W., Schröder, Fritz H., Jones, Thomas Hugh, Porst, Hartmut, Hackett, Geoffrey, Wheaton, Olivia A., Martin-Morales, Antonio, Meuleman, Eric, Cunningham, Glenn R., Divan, Hozefa A., Rosen, Raymond C., Dohle, G., Arver, S., Lenzi, A., Stroberg, P., Maggio, M., Cruz, N., Balercia, G., Yassin, A., Reisman, C., Bassa, L., Pescatori, E., Salamanca, Martinez J.I., Otero, Romero J., and Jockenhoevel, F.

Published
2017
Full Text
View/download PDF

26. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance–Ultrasound Fusion Guided Biopsy Using Local Anesthesia

Author

Immerzeel, Jos, primary, Israël, Bas, additional, Bomers, Joyce, additional, Schoots, Ivo G., additional, van Basten, Jean-Paul, additional, Kurth, Karl-Heinz, additional, de Reijke, Theo, additional, Sedelaar, Michiel, additional, Debruyne, Frans, additional, and Barentsz, Jelle, additional

Published
2022
Full Text
View/download PDF

30. Summary

Author

Barentsz, Jelle O., Debruyne, Frans M. J., Ruijs, Sjef H. J., Barentsz, Jelle O., Debruyne, Frans M. J., and Ruijs, Sjef H. J.

Published
1990
Full Text
View/download PDF

33. Clinical implementation of pre‐biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer

Author

Israël, Bas, primary, Immerzeel, Jos, additional, Leest, Marloes, additional, Hannink, Gerjon, additional, Zámecnik, Patrik, additional, Bomers, Joyce, additional, Schoots, Ivo G., additional, Basten, Jean‐Paul, additional, Debruyne, Frans, additional, Oort, Inge, additional, Sedelaar, Michiel, additional, and Barentsz, Jelle, additional

Published
2021
Full Text
View/download PDF

35. The post-finasteride syndrome: possible etiological mechanisms and symptoms

Author

Leliefeld, Herman H. J., Debruyne, Frans M. J., and Reisman, Yakov

Abstract

Finasteride and dutasteride, synthetic 5α-reductase inhibitors (5ARIs) are recommended in many guidelines for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms and alopecia despite a variety of side effects like sexual, neurological, psychiatric, endocrinological, metabolic and ophthalmological dysfunctions and the increased incidence of high grade prostate cancer. The sexual side effects are common during the use of the drug but in a small subgroup of patients, they can persist after stopping the drug. This so-called post-finasteride syndrome has serious implications for the quality of life without a clear etiology or therapy. Three types of 5α-reductases are present in many organs in- and outside the brain where they can be blocked by the two 5ARIs. There is increasing evidence that 5ARIs not only inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT) in the prostate and the scalp but also in many other tissues. The lipophilic 5ARIs can pass the blood-brain barrier and might block many other neurosteroids in the brain with changes in the neurochemistry and impaired neurogenesis. Further research and therapeutic innovations are urgently needed that might cure or relieve these side effects. More awareness is needed for physicians to outweigh these health risks against the benefits of 5ARIs.

Published
2023
Full Text
View/download PDF

37. Clinical implementation of pre‐biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer.

Author

Israël, Bas, Immerzeel, Jos, van der Leest, Marloes, Hannink, Gerjon, Zámecnik, Patrik, Bomers, Joyce, Schoots, Ivo G., van Basten, Jean‐Paul, Debruyne, Frans, van Oort, Inge, Sedelaar, Michiel, and Barentsz, Jelle

Subjects
PROSTATE cancer, MAGNETIC resonance imaging, CANCER diagnosis, DIGITAL rectal examination, PROSTATE cancer patients, PROSTATE-specific antigen
Abstract

Objective: To assess the outcomes of pre‐biopsy magnetic resonance imaging (MRI) pathways, as a tool in biopsy‐naïve men with suspicion of prostate cancer, in routine clinical practice. Secondary outcomes included a comparison of transrectal MRI‐directed biopsy (TR‐MRDB) and transperineal (TP)‐MRDB in men with suspicious MRI. Patients and Methods: We retrospectively assessed a two‐centre cohort of consecutive biopsy‐naïve men with suspicion of prostate cancer who underwent a Prostate Imaging‐Reporting and Data System version 2 (PI‐RADS v2) compliant pre‐biopsy MRI in a single, high‐volume centre between 2015 and 2019 (Centre 1). Men with suspicious MRI scans underwent TR‐MRDB in Centre 1 and TP‐MRDB with additional random biopsies (RB) in Centre 2. The MRI and histopathology were assessed in the same institution (Centre 1). Outcomes included: (i) overall detection rates of Grade Group (GG) 1, GG ≥2, and GG ≥3 cancer in men with suspicious MRI; (ii) Biopsy‐avoidance due to non‐suspicious MRI; and (iii) Cancer detection rates and biopsy‐related complications between TR‐ and TP‐MRDB. To reduce confounding bias for MRDB comparisons, inverse probability weighting (IPW) was performed for age, digital rectal examination, prostate‐specific antigen (PSA), prostate volume, PSA density, and PI‐RADS category. Results: Of the 2597 men included, the overall GG 1, GG ≥2, and GG ≥3 prevalence was 8% (210/2597), 27% (697/2597), and 15% (396/2597), respectively. Biopsy was avoided in 57% (1488/2597) of men. After IPW, the GG 1, GG ≥2 and GG ≥3 detection rates after TR‐ and TP‐MRDB were comparable at 24%, 57%, and 32%; and 18%, 64%, and 38%, respectively; with mean differences of −5.7% (95% confidence interval [CI] −13% to 1.4%), 6.1% (95% CI −2.1% to 14%), and 5.7% (95% CI −1.7% to 13%). Complications were similar in TR‐MRDB (0.50%) and TP‐MRDB with RB (0.62%; mean difference 0.11%, 95% CI −0.87% to 1.1%). Conclusion: This high‐volume, two‐centre study shows pre‐biopsy MRI as a decision tool is implementable in daily clinical practice. Compared to recent trials, a substantially higher biopsy avoidance rate was achieved without compromising GG ≥2/GG ≥3 detection and coinciding with lower over detection rates of GG 1 cancer. Prostate cancer detection and complication rates were comparable for TR‐ and TP‐MRDB. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Innovators in urology

Author

Debruyne, Frans, Buttyan, Ralph, Debruyne, Frans, Evans, Christopher, Fitzpatrick, John, Gleave, Martin, Hammerer, Peter, Kirby, Roger, Lilja, Hans, Schalken, Jack, and Soloway, Mark

Published
2003

47. Speaking fundamental frequency in monozygotic and dizygotic twins

Author

Debruyne, Frans, Decoster, Wivine, Van Gijsel, Annemie, and Vercammen, Julie

Subjects
Voice -- Genetic aspects -- Research, Twin studies -- Research, Phonetics, Acoustic -- Research, Arts, visual and performing, Health, Genetic aspects, Research
Abstract

Summary: The speaking fundamental frequency (SFF) and the intraindividual variation of the SFF during the reading of a Dutch standard text were measured in 30 female monozygotic twins (MT) and [...]

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results